With over seven million people living with HIV in South Africa, the need for effective prevention measures is critical. While the nation has made significant progress in treatment, approximately 160,000 new infections were reported last year alone.

Enter the new injectable drug, known as pre-exposure prophylaxis (PrEP), which offers a unique approach to HIV prevention. Unlike the daily oral PrEP currently available, this injection only needs to be administered once every two months.

Studies conducted in Africa have shown an impressive 89% reduction in HIV infections among users of the injectable PrEP compared to the oral version. This could be a game-changer, especially for women at high risk of contracting HIV, as it empowers them with discreet prevention options.

Despite its potential, challenges remain. The injectable PrEP, while approved for use in South Africa, comes with a hefty price tag, making it inaccessible to many. Efforts to address this issue include sharing licenses and allowing the production of generic versions of the drug.

Feedback from participants in early trials, including transgender individuals, has been overwhelmingly positive. Many prefer the convenience and effectiveness of the injection over daily pills.

Looking ahead, pilot projects for the rollout of the injectable PrEP were initially delayed but are now expected to commence in early 2024 following approval. This represents a significant step forward in South Africa's ongoing battle against HIV/AIDS.